These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 5976205)

  • 1. A double-blind evaluation of S.D. 25 in the treatment of Parkinson's disease.
    Strang RR
    Curr Med Drugs; 1966 Dec; 7(4):20-6. PubMed ID: 5976205
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical evaluation of biperiden in Parkinson's disease.
    Strang RR
    Dis Nerv Syst; 1967 Mar; 28(3):191-3. PubMed ID: 5335879
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical aspects and drug therapy of Parkinson's syndrome].
    Mumenthaler M
    Schweiz Med Wochenschr; 1966 Apr; 96(15):479-84. PubMed ID: 4862148
    [No Abstract]   [Full Text] [Related]  

  • 4. [L-Dopa therapy in Parkinson's disease. A double-blind study].
    Worm-Petersen J; Dupont E; Mikkelsen B
    Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651
    [No Abstract]   [Full Text] [Related]  

  • 5. [The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
    Kiseleva AM; Zlydnikov DM; Mazhinskaia VP; Lebedeva VK; Zakharova NG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):530-4. PubMed ID: 4705408
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of the Parkinson syndrome with amantadine].
    Hartmann-von Monakow K
    Schweiz Med Wochenschr; 1971 Dec; 101(48):1736-9. PubMed ID: 5140093
    [No Abstract]   [Full Text] [Related]  

  • 7. [The treatment of Parkinson's syndrome with L-dopa].
    Völler GW; Kerstan J
    Nervenarzt; 1970 Mar; 41(3):138-44. PubMed ID: 5447886
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical use of levodopa in the treatment of Parkinson's disease.
    McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD
    Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056
    [No Abstract]   [Full Text] [Related]  

  • 9. [Study of L-dopa treatment and its principal side effects in aged subjects].
    Antonini F; Baroni A; Bucalossi A; Roveyaz L
    Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357
    [No Abstract]   [Full Text] [Related]  

  • 10. The Graeme Robertson memorial lecture, 1983. The long-term prognosis of Parkinson's disease.
    Selby G
    Clin Exp Neurol; 1984; 20():1-25. PubMed ID: 6391761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy.
    Lipman IJ; Papadopoulos NM
    Dis Nerv Syst; 1973 Jan; 34(1):59-62. PubMed ID: 4709194
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anticholinergic treatment of Parkinson's disease (author's transl)].
    Ascher PW
    Wien Klin Wochenschr; 1976 Oct; 88(19):641-6. PubMed ID: 790774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of Parkinson's disease with levodopa. Principles. Practical advice. Considerations].
    Sigwald J
    Nouv Presse Med; 1972 Mar; 1(10):679-82. PubMed ID: 5022921
    [No Abstract]   [Full Text] [Related]  

  • 14. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

  • 15. Cholinergic-anticholinergic antagonism in parkinsonism.
    Duvoisin RC
    Arch Neurol; 1967 Aug; 17(2):124-36. PubMed ID: 4382112
    [No Abstract]   [Full Text] [Related]  

  • 16. [Psychic manifestations during treatment of Parkinson's disease with L-dopa].
    Bonduelle M
    Rev Neurol (Paris); 1970 Feb; 122(2):140. PubMed ID: 5517897
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of the preparation L-dopa in parkinsonism].
    Proniv DI; Sirotina OS; Bukhovtsev PP; Mis'kiv IaI
    Vrach Delo; 1976 Jan; (1):113-6. PubMed ID: 1246837
    [No Abstract]   [Full Text] [Related]  

  • 18. A double-blind evaluation of lysivane in the treatment of Parkinson's disease.
    Strang RR
    Br J Clin Pract; 1966 May; 20(5):249-51. PubMed ID: 5326485
    [No Abstract]   [Full Text] [Related]  

  • 19. Abnormal mouth-movements and oral damage associated with L-DOPA treatment.
    Sacks OW; Ross SJ; DePaola DP; Kohl MS
    Ann Dent; 1970; 29(4):130-44. PubMed ID: 5275661
    [No Abstract]   [Full Text] [Related]  

  • 20. [The Rorschach test in parkinsonian patients. Its course during treatment with L dopa. Its prognostic value].
    Sevilla M; Vernet JP; Becle J; Darcourt G
    Ann Med Psychol (Paris); 1973 May; 1(5):577-608. PubMed ID: 4761931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.